250 related articles for article (PubMed ID: 17471006)
1. [Guideline for the management of chronic kidney disease-related mineral and bone disorders (CKD-MBD)].
Kakuta T
Clin Calcium; 2007 May; 17(5):752-9. PubMed ID: 17471006
[TBL] [Abstract][Full Text] [Related]
2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
3. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
Al Aly Z; González EA; Martin KJ; Gellens ME
Am J Nephrol; 2004; 24(4):422-6. PubMed ID: 15308874
[TBL] [Abstract][Full Text] [Related]
4. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
Okada N; Tsubakihara Y
Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
[TBL] [Abstract][Full Text] [Related]
5. The influences of method of calcium correction and the timing of blood collection on application of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan.
Yokoyama K; Katoh N; Kasai K; Kubo H; Murai S; Shoji R; Imamura N; Saika S; Yumita S; Ishida M; Takasu S; Kono T; Yoshida Y; Wakabayashi T; Kimua Y; Hosoya T
Ther Apher Dial; 2006 Jun; 10(3):257-61. PubMed ID: 16817790
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Komaba H; Tanaka M; Fukagawa M
Intern Med; 2008; 47(11):989-94. PubMed ID: 18520108
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
[TBL] [Abstract][Full Text] [Related]
8. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
9. [Kidney and bone update : the 5-year history and future of CKD-MBD. About the guideline of the Japanese Society for Dialysis Therapy].
Yokoyama K
Clin Calcium; 2012 Jul; 22(7):979-86. PubMed ID: 22750929
[TBL] [Abstract][Full Text] [Related]
10. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
Goto S; Fukagawa M
Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
[TBL] [Abstract][Full Text] [Related]
11. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
Panawong W; Chaiyakum A; Pongskul C
J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
[TBL] [Abstract][Full Text] [Related]
12. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
[TBL] [Abstract][Full Text] [Related]
13. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
Yokoyama K
Clin Calcium; 2010 Jul; 20(7):1012-20. PubMed ID: 20585179
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
[TBL] [Abstract][Full Text] [Related]
15. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
McCarley PB; Arjomand M
Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
[TBL] [Abstract][Full Text] [Related]
16. [Renal osteodystrophy Guidelines].
Messa P;
G Ital Nefrol; 2003; 20 Suppl 24():S83-95. PubMed ID: 14666505
[TBL] [Abstract][Full Text] [Related]
17. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
[TBL] [Abstract][Full Text] [Related]
18. [Disorders of bone and mineral metabolism in CKD: CKD-MBD as a new entity].
Tsukamoto Y
Clin Calcium; 2007 May; 17(5):660-4. PubMed ID: 17470993
[TBL] [Abstract][Full Text] [Related]
19. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
[TBL] [Abstract][Full Text] [Related]
20. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
